Author: RodrÃguez de la Concepción, MarÃa Luisa; Ainsua-Enrich, Erola; Reynaga, Esteban; Ãvila-Nieto, Carlos; Santos, Jose Ramón; Roure, Silvia; Mateu, Lourdes; Paredes, Roger; Puig, Jordi; Jimenez, Juan Manuel; Izquierdo-Useros, Nuria; Clotet, Bonaventura; Pedro-Botet, MarÃa Luisa; Carrillo, Jorge
Title: High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients Cord-id: iafswu9p Document date: 2021_7_28
ID: iafswu9p
Snippet: The use of high-dose of intravenous immunoglobulins (IVIGs) as immunomodulators for the treatment of COVID-19–affected individuals has shown promising results. IVIG reduced inflammation in these patients, who progressively restored respiratory function. However, little is known about how they may modulate immune responses in COVID-19 individuals. Here, we have analyzed the levels of 41 inflammatory biomarkers in plasma samples obtained at day 0 (pretreatment initiation), 3, 7, and 14 from five
Document: The use of high-dose of intravenous immunoglobulins (IVIGs) as immunomodulators for the treatment of COVID-19–affected individuals has shown promising results. IVIG reduced inflammation in these patients, who progressively restored respiratory function. However, little is known about how they may modulate immune responses in COVID-19 individuals. Here, we have analyzed the levels of 41 inflammatory biomarkers in plasma samples obtained at day 0 (pretreatment initiation), 3, 7, and 14 from five hospitalized COVID-19 patients treated with a 5-d course of 400 mg/kg/d of IVIG. The plasmatic levels of several cytokines (Tumor Necrosis Factor, IL-10, IL-5, and IL-7), chemokines (macrophage inflammatory protein-1α), growth/tissue repairing factors (hepatic growth factor), complement activation (C5a), and intestinal damage such as Fatty acid–binding protein 2 and LPS-binding protein showed a progressive decreasing trend during the next 2 wk after treatment initiation. This trend was not observed in IVIG-untreated COVID-19 patients. Thus, the administration of high-dose IVIG to hospitalized COVID-19 patients may improve their clinical evolution by modulating their hyperinflammatory and immunosuppressive status.
Search related documents:
Co phrase search for related documents- acute acute respiratory distress syndrome and low expression: 1
- acute acute respiratory distress syndrome and lps pathway: 1, 2
- acute acute respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute lung injury and low expression: 1, 2
- acute lung injury and lps pathway: 1, 2, 3, 4, 5
- acute lung injury and lung immune infiltration: 1, 2
- acute lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute lung injury induce and lung injury: 1, 2, 3, 4, 5, 6
- acute respiratory distress syndrome and low expression: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute respiratory distress syndrome and low number: 1, 2, 3, 4, 5
- acute respiratory distress syndrome and lps pathway: 1, 2, 3, 4
- acute respiratory distress syndrome and lung immune infiltration: 1, 2, 3, 4, 5, 6
- acute respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome respiratory failure and low expression: 1
- acute respiratory distress syndrome respiratory failure and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- low expression and lung immune infiltration: 1
- low expression and lung injury: 1, 2, 3, 4
- low number and lung injury: 1
- lps pathway and lung injury: 1, 2, 3, 4, 5, 6, 7, 8
Co phrase search for related documents, hyperlinks ordered by date